P455 - NANOFORMULATED HESPERIDIN REDUCES LIVER WEIGHT MORE EFFECTIVELY THAN FREE HESPERIDIN: A COMPARATIVE EVALUATION IN A HIGH-FAT DIET AND FRUCTOSE-INDUCED METABOLIC LIVER DISEASE MODEL

P455

NANOFORMULATED HESPERIDIN REDUCES LIVER WEIGHT MORE EFFECTIVELY THAN FREE HESPERIDIN: A COMPARATIVE EVALUATION IN A HIGH-FAT DIET AND FRUCTOSE-INDUCED METABOLIC LIVER DISEASE MODEL

A. Sivaslıoğlu^1,*, Z. Göktaş¹

¹Nutrition and Dietetics, Hacettepe University, Ankara, Türkiye

Rationale: The aim of this study was to evaluate the effects of nanoformulated hesperidin (nano-hesperidin) compared to free hesperidin on liver weight in a high-fat diet and fructose-induced model of metabolic liver disease, reflecting the potential of nanoformulation for therapeutic application in liver disorders.

Methods: Female C57BL/6J mice (6-8 weeks old, n=6/group) were fed a high-fat diet with 20% fructose (20 g/100 mL) for 10 weeks to induce metabolic liver disease. For the following 10 weeks, nano (20 µM) or free hesperidin (20 µM) was administered via tail vein injection. The empty capsule (void) group was used as a suitable control for both treatment groups. The formulation of nano-hesperidin involved high-purity hesperidin, soy phosphatidylcholine, and cholesterol in chloroform. Liver weights were measured at the end of the experiment, and statistical analysis was performed using one-way ANOVA with LSD post-hoc tests.

Results: The particle size of nano-hesperidin was 185.033 nm, with a polydispersity index (PDI) of 0.311 and a zeta potential of -30.5 mV. Liver weights were 975.71±85.59 mg for free hesperidin, 825.48±54.07 mg for nano-hesperidin, and 912.28±83.13 mg for Void. Nano-hesperidin treatment significantly reduced liver weight compared to free hesperidin (p=0.004). No significant differences in liver weight were found between the Void and other groups (p > 0.05).

Conclusion: Nano-hesperidin exhibited a low PDI, high zeta potential, and favorable particle size. Nano-hesperidin significantly reduced liver weight compared to free hesperidin. The results indicate that nanoformulation may enhance hesperidin’s effects in the liver. These findings support the use of nanoformulations in the treatment of metabolic liver disorders. This study was supported by the Health Institutes of Turkey (TÜSEB) (Project no: 37247).

Disclosure of Interest: None declared